Skip to content

Study · Animal study (in vivo) · rat · 2016

8 results

Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats.

Lojo N, Rasic Z, Zenko Sever A, Kolenc D, Vukusic D, Drmic D, Zoricic I, Sever M, Seiwerth S, Sikiric P

PloS one14 Sept 2016Cited by 46 (Europe PMC)

PMID27627764 (opens in a new tab)PMCIDPMC5023193 (opens in a new tab)DOI10.1371/journal.pone.0162590 (opens in a new tab)PepBankPUB-27627764
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Stable gastric pentadecapeptide BPC 157 was previously used to ameliorate wound healing following major surgery and counteract diclofenac toxicity. To resolve the increasing early risks following major massive small bowel resectioning surgery, diclofenac combined with nitric oxide (NO) system blockade was used, suggesting therapy with BPC 157 and the nitric oxide synthase (NOS substrate) L-arginine, is efficacious. Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later. Short-bowel rats exhibited poor anastomosis healing, failed intestine adaptation, and gastrointestinal, liver, and brain lesions, which worsened with diclofenac. This was gradually ameliorated by immediate therapy with BPC 157 and L-arginine. Contrastingly, NOS-blocker L-NAME induced further aggravation and lesions gradually worsened. Specifically, rats with surgery alone exhibited mild stomach/duodenum lesions, considerable liver lesions, and severe cerebral/hippocampal lesions while those also administered diclofenac showed widespread severe lesions in the gastrointestinal tract, liver, cerebellar nuclear/Purkinje cells, and cerebrum/hippocampus. Rats subjected to surgery, diclofenac, and L-NAME exhibited the mentioned lesions, worsening anastomosis, and macro/microscopical necrosis. Thus, rats subjected to surgery alone showed evidence of deterioration. Furtheremore, rats subjected to surgery and administered diclofenac showed worse symptoms, than the rats subjected to surgery alone did. Rats subjected to surgery combined with diclofenac and L-NAME showed the worst deterioration. Rats subjected to surgery exhibited habitual adaptation of the remaining small intestine, which was markedly reversed in rats subjected to surgery and diclofenac, and those with surgery, diclofenac, and L-NAME. BPC 157 completely ameliorated symptoms in massive intestinal resection-, massive intestinal resection plus diclofenac-, and massive intestinal resection plus diclofenac plus L-NAME-treated short bowel rats that presented with cyclooxygenase (COX)-NO-system inhibition. L-arginine ameliorated only L-NAME-induced aggravation of symptoms in rats subjected to massive intestinal resection and administered diclofenac plus L-NAME.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In short-bowel rats after massive intestinal resection, BPC‑157 completely ameliorated symptoms.

    In plain wordsIn rats with short bowel after surgery, BPC‑157 completely eased the symptoms.

    Peptide
    BPC-157
    Outcome
    DecreaseSymptoms after massive intestinal resection
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal · 24 hoursAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 completely ameliorated symptoms in massive intestinal resection-, massive intestinal resection plus diclofenac-, and massive intestinal resection plus diclofenac plus L-NAME-treated short bowel rats
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In short-bowel rats given diclofenac, BPC‑157 completely ameliorated symptoms.

    In plain wordsIn short-bowel rats given diclofenac, BPC‑157 completely eased the symptoms.

    Peptide
    BPC-157
    Outcome
    DecreaseSymptoms after massive intestinal resection plus diclofenac
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal · 24 hoursAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 completely ameliorated symptoms in massive intestinal resection-, massive intestinal resection plus diclofenac-, and massive intestinal resection plus diclofenac plus L-NAME-treated short bowel rats that presented with cyclooxygenase (COX)-NO-system inhibition.
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In short-bowel rats given diclofenac and L-NAME, BPC‑157 completely ameliorated symptoms.

    In plain wordsIn short-bowel rats given diclofenac and L-NAME, BPC‑157 completely eased the symptoms.

    Peptide
    BPC-157
    Outcome
    DecreaseSymptoms after massive intestinal resection plus diclofenac plus L-NAME
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal · 24 hoursAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 completely ameliorated symptoms in massive intestinal resection-, massive intestinal resection plus diclofenac-, and massive intestinal resection plus diclofenac plus L-NAME-treated short bowel rats that presented with cyclooxygenase (COX)-NO-system inhibition.
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.

Studies that did not test the peptide alone5

In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking BPC-157.

  1. 04AnimalNot a test of BPC-157 aloneAnimal study (in vivo)Efficacy outcome

    In short-bowel rats, poor anastomosis healing was gradually ameliorated by immediate therapy with BPC‑157 and L-arginine.

    In plain wordsIn short-bowel rats, poor healing of the join in the bowel improved gradually with BPC‑157 and L-arginine.

    Peptide
    BPC-157
    Outcome
    IncreaseAnastomosis healing
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Wound healing · Gastrointestinal

    Source sentences

    Summary
    Short-bowel rats exhibited poor anastomosis healing, failed intestine adaptation, and gastrointestinal, liver, and brain lesions, which worsened with diclofenac. This was gradually ameliorated by immediate therapy with BPC 157 and L-arginine.
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  2. 05AnimalNot a test of BPC-157 aloneAnimal study (in vivo)Efficacy outcome

    In short-bowel rats, failed intestinal adaptation was gradually ameliorated by immediate therapy with BPC‑157 and L-arginine.

    In plain wordsIn short-bowel rats, failed adaptation of the bowel improved gradually with BPC‑157 and L-arginine.

    Peptide
    BPC-157
    Outcome
    IncreaseIntestinal adaptation
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    Short-bowel rats exhibited poor anastomosis healing, failed intestine adaptation, and gastrointestinal, liver, and brain lesions, which worsened with diclofenac. This was gradually ameliorated by immediate therapy with BPC 157 and L-arginine.
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  3. 06AnimalNot a test of BPC-157 aloneAnimal study (in vivo)Efficacy outcome

    In short-bowel rats, gastrointestinal lesions were gradually ameliorated by immediate therapy with BPC‑157 and L-arginine.

    In plain wordsIn short-bowel rats, gut lesions eased gradually with BPC‑157 and L-arginine.

    Peptide
    BPC-157
    Outcome
    DecreaseGastrointestinal lesions
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    Short-bowel rats exhibited poor anastomosis healing, failed intestine adaptation, and gastrointestinal, liver, and brain lesions, which worsened with diclofenac. This was gradually ameliorated by immediate therapy with BPC 157 and L-arginine.
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  4. 07AnimalNot a test of BPC-157 aloneAnimal study (in vivo)Efficacy outcome

    In short-bowel rats, liver lesions were gradually ameliorated by immediate therapy with BPC‑157 and L-arginine.

    In plain wordsIn short-bowel rats, liver lesions eased gradually with BPC‑157 and L-arginine.

    Peptide
    BPC-157
    Outcome
    DecreaseLiver lesions
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Short-bowel rats exhibited poor anastomosis healing, failed intestine adaptation, and gastrointestinal, liver, and brain lesions, which worsened with diclofenac. This was gradually ameliorated by immediate therapy with BPC 157 and L-arginine.
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

  5. 08AnimalNot a test of BPC-157 aloneAnimal study (in vivo)Efficacy outcome

    In short-bowel rats, brain lesions were gradually ameliorated by immediate therapy with BPC‑157 and L-arginine.

    In plain wordsIn short-bowel rats, brain lesions eased gradually with BPC‑157 and L-arginine.

    Peptide
    BPC-157
    Outcome
    DecreaseBrain lesions
    Study

    ratn: not reported in source

    Comparator
    Untreated short-bowel rats
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Short-bowel rats exhibited poor anastomosis healing, failed intestine adaptation, and gastrointestinal, liver, and brain lesions, which worsened with diclofenac. This was gradually ameliorated by immediate therapy with BPC 157 and L-arginine.
    1 context sentence
    Summary · context
    Immediately after anastomosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5 mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later.

    In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.